Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 12/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30561183 | 1.00 | PTPN11 (0.59) | PTPN11KCNH2EGFRHDAC3HDAC4 | |
| SCHEMBL30594000 | 1.00 | PTPN11 (0.59) | PTPN11KCNH2EGFRHDAC3HDAC4 | |
| SCHEMBL20417883 | 0.90 | PTPN11 (0.47) | PTPN11KCNH2EGFRHDAC3HDAC4 | |
| SCHEMBL25364834 | 0.90 | PTPN11 (0.65) | PTPN11KCNH2EGFRHDAC3HDAC4 | |
| SCHEMBL20418044 | 0.86 | PTPN11 (0.47) | PTPN11KCNH2EGFRHDAC3HDAC4 | |
| SCHEMBL30561102 | 0.86 | PTPN11 (0.47) | PTPN11KCNH2EGFRHDAC3HDAC4 | |
| SCHEMBL20415558 | 0.82 | PTPN11 (0.49) | PTPN11KCNH2EGFRHDAC3HDAC4 | |
| SCHEMBL30221950 | 0.82 | PTPN11 (0.49) | PTPN11KCNH2EGFRHDAC3HDAC4 | |
| SCHEMBL21115213 | 0.82 | HDAC3 (0.57) | PTPN11KCNH2HDAC3HDAC4HDAC1 | |
| SCHEMBL25365256 | 0.82 | PTPN11 (0.56) | PTPN11KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3571199-B1 | BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | REVOLUTION MEDICINES INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260103469-A1 | BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | REVOLUTION MEDICINES INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12365688-B2 | Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2025-07-22 | — | — | US | disclosed |
| US-20240199616-A1 | BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-06-20 | — | — | US | disclosed |
| CN-117327075-A | Bicyclic compounds as allosteric SHP2 inhibitors | 锐新医药公司 | 2024-01-02 | — | — | CN | disclosed |
| CN-110446709-B | Bicyclic compounds as allosteric SHP2 inhibitors | 锐新医药公司 | 2023-09-12 | — | — | CN | disclosed |
| US-11739093-B2 | Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739093-B2 | Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739093-B2 | Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| WO-2018136265-A1 | BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. (US) | 2018-07-26 | — | — | WO | disclosed |
| WO-2018136265-A1 | BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. (US) | 2018-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199616-A1 | BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | PTPN18, PTPN1, PTPN2 | PTPN11 12/4885KCNH2 4409/4885EGFR 381/4885 |
| US-12365688-B2 | Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors | PTPN5, PTPN2, PTPN1 | PTPN11 13/4885KCNH2 3022/4885EGFR 727/4885 |
| US-20260103469-A1 | BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | PTPN5, PTPN6, PTPN1 | PTPN11 9/4885KCNH2 2888/4885EGFR 245/4885 |
| US-11739093-B2 | Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors | PTPN5, PTPN2, PTPN4 | PTPN11 9/4885KCNH2 2990/4885EGFR 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.